Cytek expands Cloud Analysis and Cytek Biosciences stock costs EUR 5.18

Cytek Biosciences has expanded its Cytek Cloud platform by introducing a new Cloud Analysis tool and a Premium subscription tier. The platform, which has over 28,000 users, allows researchers to import experimental data and perform analysis in the cloud, aiming to integrate a subscription feature into existing research workflows. Despite a 6% increase in Q2 2026 revenue to $48.10 million, the company reported an increased net loss of $12.20 million, although it raised the lower end of its full-y